falconer or anyone else's opinion , IYO are multiple partners in the future for Anavex's expanding pipeline?
I'm wondering if there will be so many diseases and conditions not listed yet in the Anavex pipeline that Anavex's drug portfolio can successfully treat, if there will be multiple partners in the future besides Alzheimer. Such as epilepsy, seizures, stroke, depression, neurodegenerative diseases, multiple sclerosis, depression, cancer, heart disease, REM sleep, age related macular degeneration, visceral pain, acute neuropathic pain, autism, high blood pressure, etc, etc ?
The sigma-1 receptor (Sig-1R / SIGMAR1) that 2-73 Blarcamesine brings back into proper homeostasis between the endoplasmic reticulum and the mitochondria is found throughout the body and in all organs. That opens up a wide range of diseases and conditions that Anavex's 2-73 Blarcamesine, and including A3-71 and other drugs in the Anavex drug portfolio that can be a treatment to bring the entire body back into homeostasis and a healthy condition.
Considering that the numerous diseases and conditions that the Anavex's drug portfolio could treat is a huge load for a small biotech, I would not be surprised to see multiple partners in the future that 'specializes' in these wide range of diseases and conditions located throughout the body to handle the trials and marketing, with Anavex taking a percentage of the gross revenues without spending it's own time and funds.